Cytokinetics (CYTK) reported late Wednesday Q3 net loss of $1.36 per share, wider than the $1.35 loss per share a year earlier.
Analysts polled by Capital IQ expected $1.27 loss per share.
Revenue for the quarter ended Sept. 30 was $463,000, up from $378,000 a year earlier.
Analysts polled by Capital IQ expected $1.2 million.
The company had $1.3 billion in cash, cash equivalents, and investments at Sept. 30, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments